Gastrointestinal Cancer
From the Journals
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
Patients were randomized to receive either 10 minutes of immersive VR distraction therapy or 10 minutes of two-dimensional guided imagery...
Conference Coverage
Certain Pesticides Linked With Risk for Pancreatic Cancer
Researcher divided the entire French territory into 5529 spatial units and determined the number of pancreatic cancer cases per spatial unit per...
Commentary
A Banned Chemical That Is Still Causing Cancer
This carcinogen ‘is still around: in our soil, in our food, and in our blood.’
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...
News
Liquid Biopsy for Colorectal Cancer Appears Promising But Still Lacks Robust Efficacy
Patients who may have declined colonoscopy should understand the need for a colonoscopy if blood-based tests show abnormal results.
From the Journals
Few Childhood Cancer Survivors Get Recommended Screenings
‘As many as four out of five of these survivors will develop a serious or life-threatening late effect of their cancer therapy by age 45,’ the...
Latest News
New CRC Risk Prediction Model Outperforms Polyp-Based Model
The comprehensive model included baseline colonoscopy indication, age group, diabetes diagnosis, and polyp findings.
From the Journals
New CRC stool test beats FIT for sensitivity but not specificity
The higher specificity for advanced lesions is expected to translate to a lower false positive rate.
From the Journals
Most Cancer Trial Centers Located Closer to White, Affluent Populations
Researchers compare the distributions of patients of different races and socioeconomic statuses to the locations of clinical research facilities...
Commentary
New Drug Approvals Are the Wrong Metric for Cancer Policy
How should we define success in cancer policy — what should the endpoint be?
Feature
Extraordinary Patients Inspired Father of Cancer Immunotherapy
Renowned researcher, Dr. Steven A. Rosenberg, describes his path to pioneering the use of immunotherapies in treating cancer.